Response from the Canadian Children Inflammatory Bowel Disease Network to the US Food and Drug Administration Draft Guidance for Industry on pediatric inflammatory bowel disease: developing drugs for treatment.
作者信息
Wine Eytan, deBruyn Jennifer, Crowley Eileen, Griffiths Anne M
机构信息
Canadian Children Inflammatory Bowel Disease Network, Canada.
Division of Pediatric Gastroenterology, Department of Pediatrics, University of Alberta, Edmonton, AB T6G1C9,Canada.
出版信息
J Can Assoc Gastroenterol. 2024 Oct 12;7(6):397-398. doi: 10.1093/jcag/gwae034. eCollection 2024 Dec.
Abstract
摘要
相似文献
1
Response from the Canadian Children Inflammatory Bowel Disease Network to the US Food and Drug Administration Draft Guidance for Industry on pediatric inflammatory bowel disease: developing drugs for treatment.加拿大儿童炎症性肠病网络对美国食品药品监督管理局关于儿童炎症性肠病治疗药物研发的行业指南草案的回应
J Can Assoc Gastroenterol. 2024 Oct 12;7(6):397-398. doi: 10.1093/jcag/gwae034. eCollection 2024 Dec.
2
Developing drugs for treatment of atopic dermatitis in children (≥3 months to <18 years of age): Draft guidance for industry.开发用于治疗儿童（≥3个月至<18岁）特应性皮炎的药物：行业指南草案。
Pediatr Dermatol. 2018 May;35(3):303-322. doi: 10.1111/pde.13452. Epub 2018 Mar 30.
3
4
Workshop report: developing a pediatric inflammatory bowel diseases network and data platform in Canada.工作坊报告：在加拿大开发小儿炎症性肠病网络和数据平台。
J Pediatr Gastroenterol Nutr. 2012 Aug;55(2):125-30. doi: 10.1097/MPG.0b013e3182604f3c.
5
Allied Health Professional Support in Pediatric Inflammatory Bowel Disease: A Survey from the Canadian Children Inflammatory Bowel Disease Network-A Joint Partnership of CIHR and the CH.I.L.D. Foundation.儿科炎症性肠病中的辅助健康专业人员支持：来自加拿大儿童炎症性肠病网络的调查-该网络是由加拿大卫生研究院和 CH.I.L.D. 基金会联合成立的合作组织。
Can J Gastroenterol Hepatol. 2017;2017:3676474. doi: 10.1155/2017/3676474. Epub 2017 May 16.
6
Use of Placebo in Pediatric Inflammatory Bowel Diseases: A Position Paper From ESPGHAN, ECCO, PIBDnet, and the Canadian Children IBD Network.安慰剂在儿童炎症性肠病中的应用：来自欧洲儿科胃肠病、肝病和营养学会（ESPGHAN）、欧洲克罗恩病和结肠炎组织（ECCO）、儿童炎症性肠病研究网络（PIBDnet）以及加拿大儿童炎症性肠病网络的立场文件。
J Pediatr Gastroenterol Nutr. 2016 Jan;62(1):183-7. doi: 10.1097/MPG.0000000000001024.
7
Inflammatory Bowel Disease Among Canadian Children: Comparison Between Children of Non-European Descent and Children of European Descent.加拿大儿童炎症性肠病：非欧裔和欧裔儿童的比较。
Inflamm Bowel Dis. 2023 Nov 2;29(11):1760-1768. doi: 10.1093/ibd/izac276.
8
Developing Drugs for Prevention of Chemotherapy-Induced Nausea and Vomiting: Draft Guidance from the FDA.开发预防化疗引起的恶心和呕吐的药物：FDA 的指南草案。
Clin Cancer Res. 2021 Nov 15;27(22):6072-6074. doi: 10.1158/1078-0432.CCR-21-1941. Epub 2021 Jul 15.
9
How a patient advocacy group developed the first proposed draft guidance document for industry for submission to the U.S. Food and Drug Administration.一个患者权益倡导组织如何制定了首份拟提交给美国食品药品监督管理局的行业指导文件草案。
Orphanet J Rare Dis. 2015 Jun 24;10:82. doi: 10.1186/s13023-015-0281-2.
10
The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.《2018年炎症性肠病在加拿大的影响：患有炎症性肠病的儿童和青少年》
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S49-S67. doi: 10.1093/jcag/gwy056. Epub 2018 Nov 2.
引用本文的文献
1
Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation.小儿溃疡性结肠炎的管理，第1部分：门诊护理——欧洲儿科胃肠病学、肝病学和营养学会以及欧洲克罗恩病和结肠炎组织的循证共识指南更新版
J Pediatr Gastroenterol Nutr. 2025 Sep;81(3):765-815. doi: 10.1002/jpn3.70097. Epub 2025 Jul 18.
2
Children With Inflammatory Bowel Diseases are Disadvantaged by Current Drug Approval Policies: A Call for Urgent Change.炎症性肠病患儿因当前的药物审批政策而处于不利地位：呼吁紧急变革。
Crohns Colitis 360. 2025 Jun 19;7(2):otaf036. doi: 10.1093/crocol/otaf036. eCollection 2025 Apr.
Zotero 插件